The Max Planck Society together with Astra Zeneca and Merck KGaA, Darmstadt, Germany, plans to appoint

**Three Independent Junior Group Leaders**
in the **Chemical Genomics Centre** of the **Max Planck Society** in Dortmund; Germany

The Chemical Genomics Centre (CGC) was established in 2005 by the Max-Planck Society (MPG) as collaboration with several pharmaceutical companies to address challenging scientific problems, to explore and validate high-risk approaches and to generate cutting edge precompetitive research which could enable the development of translational science in the medium to long term. The CGC network interconnects the scientific, infrastructural and institutional strength of well-established Max-Planck Departments with new research groups bringing in intellectual talent and novel scientific approaches. It has a proven track record from its first two funding periods (2006-2011; 2012-2017), and will serve as a role model for excellent and fruitful collaborations between academic research and industry again in the third funding period (2018-2023). (For more information about the CGC and its track record see [www.cgc.mpg.de](http://www.cgc.mpg.de)).

During the third funding period of the CGC (2018-2023), three Junior Group Leader positions are available. These include direct access to fully furnished laboratories and funding to start their independent research group. Candidates that have already gained research experience, are passionate to realize high-level research projects, and interested to qualify for future Professorships or other scientific leadership positions are welcome to apply.

Successful candidates will have a strong background in chemical biology, medicinal chemistry, organic chemistry or a related area as proven by an excellent publication record. Group Leaders usually hold an advanced degree with at least one year post-doctoral experience. The 5-years contract is for a Group Leader at the Junior Professor level, starting in 2018. Funding will be provided in collaboration with the CGC of the MPG, Astra Zeneca and Merck KGaA, and includes support for the Group Leader position, Ph.D. students and Post Docs.

The CGC develops novel chemical biology, chemistry and biology and approaches to gain novel insight into biological systems. The independent groups will focus on a topic of chemical biology, including, but not limited to Noncanonical Functions of Proteins, Druggability of RNA and RNA-Protein Complexes and Small Molecule Target Deconvolution Strategies.
Ambitious candidates looking to make high-impact discoveries with very attractive research proposals on the chemical biology field are welcomed to apply.

The groups will be located in well-equipped laboratories in the BioMedizinZentrum (BMZ) Dortmund. The BMZ is situated in the Technische Universität Dortmund Campus where it benefits from a strong collaborative, inter-sectorial network of R&D entities such as the Max Planck Institute of Molecular Physiology (MPI), the Lead Discovery Center (LDC), the Technische Universität Dortmund (TUDo), the Compound Management and Screening Center (COMAS), the Zentrum für Integrierte Wirkstoffforschung (ZIW), and the Faculty of the International Max Planck Research School of Chemical Biology (IMPRS).

Candidates will be invited to submit their application and later upon selection be asked to present their research proposal, in English, at the Max Planck Institute in Dortmund on 24th-25th January, 2018.

The Max-Planck Society is committed to increasing the number of individuals with disabilities in its workforce and therefore encourages applications from such qualified individuals.

The Max-Planck Society seeks to increase the number of women in those areas where they are underrepresented and therefore explicitly encourages women to apply.

Applications including CV, publication list, research proposal (10 pages maximum), in English, and two letters of recommendation should be sent to Debora Bruzzese, e-mail: debora.bruzzese@mpi-dortmund.mpg.de, who can also be contacted for additional information, before November 10th, 2017.